

## **Supplementary Figure S1: Final Survey**

### **Socio-demographic and centre data of the participant**

Age

Gender

Length of practice

Specialty

Geographic location of practice

Number of ovarian cancers managed per year by your institution

Number of surgeons operating on ovarian cancers in your facility

Number of trials opened for ovarian cancer (including early stage)

Possession of ESGO accreditation

Extension work-up performed

Review of imaging and pathology data

Use of O-RADS MRI score in your centre

Data on files presented in the multidisciplinary team

Members of the multidisciplinary team

Presence of a geriatric oncologist

### **Pathological/genetic data**

Condition of anatomo-pathological review

Time (months) to obtain an oncogenetic consultation

Conditions relating to searching for and obtaining the somatic and/or germline BRCA mutation and/or HRD

### **Surgery**

Mean time from first consultation to cytoreduction surgery for patients who are operable at the outset

Percentage of patients who have first surgery

Use of standardised ESGO-type operative report?

Use of resectability scores for peritoneal carcinosis and method of evaluation

Criteria for deciding on primary surgery

Data on laparoscopy performance

Data on the realisation of the lymph node surgery: imaging, use of LIONS criteria

Types of surgical procedures performed by the practitioner

Data on CHIP and PIPAC

### **Chemotherapy**

Average time between first consultation and first chemotherapy

Types of treatment performed according to BRCA status, surgery (neo-adjuvant, adjuvant, CCO or CC1): chemotherapy, bevacizumab, PARP inhibitors

### **Follow-up**


Monitoring tools used

**Supplementary Table S1.** Percentage of response and specialty of participants for each section

| <b>Parameters</b>                                       | <b>Respondents (%)</b> |
|---|------------------------|
| Answers to pathological questions – no <sup>1</sup> (%) | 34 (37.8)              |
| Medical oncologist - no. (%)                            | 8 (23.5)               |
| Obstetrician-gynaecologist - no. (%)                    | 11 (32.4)              |
| Surgical oncologist - no. (%)                           | 10 (29.4)              |

|  |           |
|--|-----------|
| Geriatric oncologist - no. (%)                 | 0 (0)     |
| Pathologist - no. (%)                          | 5 (14.7)  |
| Answers to surgery questions - no (%)          | 83 (77.6) |
| Medical oncologist - no. (%)                   | 5 (6.0)   |
| Obstetrician-gynaecologist - no. (%)           | 40 (48.2) |
| Surgical oncologist - no. (%)                  | 37 (44.6) |
| Geriatric oncologist - no. (%)                 | 0 (0)     |
| Pathologist - no. (%)                          | 1 (1.2)   |
| Answers to medical oncology questions - no (%) | 33 (30.8) |
| Medical oncologist - no. (%)                   | 19 (57.6) |
| Obstetrician-gynaecologist - no. (%)           | 6 (18.2)  |
| Surgical oncologist - no. (%)                  | 7 (21.2)  |
| Geriatric oncologist - no. (%)                 | 1 (3.0)   |
| Pathologist - no. (%)                          | 0 (0)     |

<sup>1</sup> Number of respondents.



**Supplementary Figure S2.** Percentage of participants according to their application of the LION criteria during PDS and/or IDS.